# A Study of KC1036 in Patients with Advanced Thymic Tumors

Source: https://onco.cc/trials/nct05683886/  
OnCo record `nct05683886` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of KC1036 in thymoma and thymic carcinoma, run by Beijing Konruns Pharmaceutical Co., Ltd., now recruiting.

## Summary

A Study of KC1036 in Patients with Advanced Thymic Tumors is a phase 2 interventional study registered as NCT05683886 by Beijing Konruns Pharmaceutical Co., Ltd., with 30 participants planned, started 2023-02-22 and due to reach its primary completion in 2025-02. Interventions recorded: KC1036.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05683886
- Phase: 2
- Setting: A Single-arm, Open, Multicenter, Phase II Study to Evaluate the Efficacy and Safety of KC1036 in the Patients with Advanced Recurrent or Metastatic Thymic Tumors
- Sponsor: Beijing Konruns Pharmaceutical Co., Ltd.
- Enrolled: 30

## Sources

- ClinicalTrials.gov NCT05683886: https://clinicaltrials.gov/study/NCT05683886

## Connected records

- cancers: [Thymoma and thymic carcinoma](https://onco.cc/cancers/thymic-epithelial/)
- drugs: [KC1036](https://onco.cc/drugs/kc1036/)
- companies: [Beijing Konruns Pharmaceutical](https://onco.cc/companies/beijing-konruns-pharmaceutical/)

---
JSON: https://onco.cc/api/v1/entities/nct05683886.json